ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

CordenPharma will buy a Pfizer pharmaceutical plant

by Michael McCoy
October 16, 2017 | APPEARED IN VOLUME 95, ISSUE 41

The pharmaceutical chemical company CordenPharma has agreed to acquire a high-containment active pharmaceutical ingredient (API) facility from Pfizer in Boulder, Colo. The plant, which Pfizer acquired as part of its 2015 purchase of Hospira, has production capabilities ranging from small scale to 3,000 L and more than 100 employees. CordenPharma, which is part of International Chemical Investors Group, has acquired several API plants in recent years, including a Roche peptides facility that’s also in Boulder.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment